PortalPublikationenA Two-Center Randomized Trial of an Additional Early Dose of...

A Two-Center Randomized Trial of an Additional Early Dose of Measles Vaccine

Standard

A Two-Center Randomized Trial of an Additional Early Dose of Measles Vaccine. / Fisker, Ane B; Nebie, Eric; Schoeps, Anja; Martins, Cesario; Rodrigues, Amabelia; Zakane, Alphonse; Kagone, Moubassira; Byberg, Stine; Thysen, Sanne M; Tiendrebeogo, Justin; Coulibaly, Boubacar; Sankoh, Osman; Becher, Heiko; Whittle, Hilton C; van der Klis, Fiona R M; Benn, Christine S; Sie, Ali; Müller, Olaf; Aaby, Peter.

in: CLIN INFECT DIS, Jahrgang 66, Nr. 10, 02.05.2018, S. 1573-1580.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Fisker, AB, Nebie, E, Schoeps, A, Martins, C, Rodrigues, A, Zakane, A, Kagone, M, Byberg, S, Thysen, SM, Tiendrebeogo, J, Coulibaly, B, Sankoh, O, Becher, H, Whittle, HC, van der Klis, FRM, Benn, CS, Sie, A, Müller, O & Aaby, P 2018, 'A Two-Center Randomized Trial of an Additional Early Dose of Measles Vaccine', CLIN INFECT DIS, Jg. 66, Nr. 10, S. 1573-1580. https://doi.org/10.1093/cid/cix1033

APA

Fisker, A. B., Nebie, E., Schoeps, A., Martins, C., Rodrigues, A., Zakane, A., Kagone, M., Byberg, S., Thysen, S. M., Tiendrebeogo, J., Coulibaly, B., Sankoh, O., Becher, H., Whittle, H. C., van der Klis, F. R. M., Benn, C. S., Sie, A., Müller, O., & Aaby, P. (2018). A Two-Center Randomized Trial of an Additional Early Dose of Measles Vaccine. CLIN INFECT DIS, 66(10), 1573-1580. https://doi.org/10.1093/cid/cix1033

Vancouver

Fisker AB, Nebie E, Schoeps A, Martins C, Rodrigues A, Zakane A et al. A Two-Center Randomized Trial of an Additional Early Dose of Measles Vaccine. CLIN INFECT DIS. 2018 Mai 2;66(10):1573-1580. https://doi.org/10.1093/cid/cix1033

Bibtex

@article{7b0828f979d44b8297d290b2b192808f,
title = "A Two-Center Randomized Trial of an Additional Early Dose of Measles Vaccine",
abstract = "Background: In addition to protecting against measles, measles vaccine (MV) may have beneficial nonspecific effects. We tested the effect of an additional early MV on mortality and measles antibody levels.Methods: Children aged 4-7 months at rural health and demographic surveillance sites in Burkina Faso and Guinea-Bissau were randomized 1:1 to an extra early standard dose of MV (Edmonston-Zagreb strain) or no extra MV 4 weeks after the third diphtheria-tetanus-pertussis-hepatitis B-Haemophilus influenzae type b vaccine. All children received routine MV at 9 months. We assessed mortality through home visits and compared mortality from enrollment to age 3 years using Cox proportional hazards models, censoring for subsequent nontrial MV. Subgroups of participants had blood sampled to assess measles antibody levels.Results: Among 8309 children enrolled from 18 July 2012 to 3 December 2015, we registered 145 deaths (mortality rate: 16/1000 person-years). The mortality was lower than anticipated and did not differ by randomization group (hazard ratio, 1.05; 95% confidence interval, 0.75-1.46). At enrollment, 4% (16/447) of children in Burkina Faso and 21% (90/422) in Guinea-Bissau had protective measles antibody levels. By age 9 months, no measles-unvaccinated/-unexposed child had protective levels, while 92% (306/333) of early MV recipients had protective levels. At final follow-up, 98% (186/189) in the early MV group and 97% (196/202) in the control group had protective levels.Conclusions: Early MV did not reduce all-cause mortality. Most children were susceptible to measles infection at age 4-7 months and responded with high antibody levels to early MV.Clinical Trials Registration: NCT01644721.",
keywords = "Journal Article",
author = "Fisker, {Ane B} and Eric Nebie and Anja Schoeps and Cesario Martins and Amabelia Rodrigues and Alphonse Zakane and Moubassira Kagone and Stine Byberg and Thysen, {Sanne M} and Justin Tiendrebeogo and Boubacar Coulibaly and Osman Sankoh and Heiko Becher and Whittle, {Hilton C} and {van der Klis}, {Fiona R M} and Benn, {Christine S} and Ali Sie and Olaf M{\"u}ller and Peter Aaby",
year = "2018",
month = may,
day = "2",
doi = "10.1093/cid/cix1033",
language = "English",
volume = "66",
pages = "1573--1580",
journal = "CLIN INFECT DIS",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "10",

}

RIS

TY - JOUR

T1 - A Two-Center Randomized Trial of an Additional Early Dose of Measles Vaccine

AU - Fisker, Ane B

AU - Nebie, Eric

AU - Schoeps, Anja

AU - Martins, Cesario

AU - Rodrigues, Amabelia

AU - Zakane, Alphonse

AU - Kagone, Moubassira

AU - Byberg, Stine

AU - Thysen, Sanne M

AU - Tiendrebeogo, Justin

AU - Coulibaly, Boubacar

AU - Sankoh, Osman

AU - Becher, Heiko

AU - Whittle, Hilton C

AU - van der Klis, Fiona R M

AU - Benn, Christine S

AU - Sie, Ali

AU - Müller, Olaf

AU - Aaby, Peter

PY - 2018/5/2

Y1 - 2018/5/2

N2 - Background: In addition to protecting against measles, measles vaccine (MV) may have beneficial nonspecific effects. We tested the effect of an additional early MV on mortality and measles antibody levels.Methods: Children aged 4-7 months at rural health and demographic surveillance sites in Burkina Faso and Guinea-Bissau were randomized 1:1 to an extra early standard dose of MV (Edmonston-Zagreb strain) or no extra MV 4 weeks after the third diphtheria-tetanus-pertussis-hepatitis B-Haemophilus influenzae type b vaccine. All children received routine MV at 9 months. We assessed mortality through home visits and compared mortality from enrollment to age 3 years using Cox proportional hazards models, censoring for subsequent nontrial MV. Subgroups of participants had blood sampled to assess measles antibody levels.Results: Among 8309 children enrolled from 18 July 2012 to 3 December 2015, we registered 145 deaths (mortality rate: 16/1000 person-years). The mortality was lower than anticipated and did not differ by randomization group (hazard ratio, 1.05; 95% confidence interval, 0.75-1.46). At enrollment, 4% (16/447) of children in Burkina Faso and 21% (90/422) in Guinea-Bissau had protective measles antibody levels. By age 9 months, no measles-unvaccinated/-unexposed child had protective levels, while 92% (306/333) of early MV recipients had protective levels. At final follow-up, 98% (186/189) in the early MV group and 97% (196/202) in the control group had protective levels.Conclusions: Early MV did not reduce all-cause mortality. Most children were susceptible to measles infection at age 4-7 months and responded with high antibody levels to early MV.Clinical Trials Registration: NCT01644721.

AB - Background: In addition to protecting against measles, measles vaccine (MV) may have beneficial nonspecific effects. We tested the effect of an additional early MV on mortality and measles antibody levels.Methods: Children aged 4-7 months at rural health and demographic surveillance sites in Burkina Faso and Guinea-Bissau were randomized 1:1 to an extra early standard dose of MV (Edmonston-Zagreb strain) or no extra MV 4 weeks after the third diphtheria-tetanus-pertussis-hepatitis B-Haemophilus influenzae type b vaccine. All children received routine MV at 9 months. We assessed mortality through home visits and compared mortality from enrollment to age 3 years using Cox proportional hazards models, censoring for subsequent nontrial MV. Subgroups of participants had blood sampled to assess measles antibody levels.Results: Among 8309 children enrolled from 18 July 2012 to 3 December 2015, we registered 145 deaths (mortality rate: 16/1000 person-years). The mortality was lower than anticipated and did not differ by randomization group (hazard ratio, 1.05; 95% confidence interval, 0.75-1.46). At enrollment, 4% (16/447) of children in Burkina Faso and 21% (90/422) in Guinea-Bissau had protective measles antibody levels. By age 9 months, no measles-unvaccinated/-unexposed child had protective levels, while 92% (306/333) of early MV recipients had protective levels. At final follow-up, 98% (186/189) in the early MV group and 97% (196/202) in the control group had protective levels.Conclusions: Early MV did not reduce all-cause mortality. Most children were susceptible to measles infection at age 4-7 months and responded with high antibody levels to early MV.Clinical Trials Registration: NCT01644721.

KW - Journal Article

U2 - 10.1093/cid/cix1033

DO - 10.1093/cid/cix1033

M3 - SCORING: Journal article

C2 - 29177407

VL - 66

SP - 1573

EP - 1580

JO - CLIN INFECT DIS

JF - CLIN INFECT DIS

SN - 1058-4838

IS - 10

ER -